Board Resolves to Increase Capital in Subsidiary
Original: 公告本公司董事會決議增資子公司
Summary
Largan Precision's Board of Directors has passed a resolution to inject additional capital into one or more of its subsidiaries. Such a move typically signals strategic investment in subsidiary operations, capacity expansion, or internal restructuring. The specific subsidiary, injection amount, funding source, and rationale are available only in the full filing on MOPS.
Full Translation
Largan Precision Co., Ltd. (TWSE: 3008) announces that its Board of Directors has resolved to increase the registered capital of a subsidiary (capital injection / paid-in capital increase at the subsidiary level). Under Taiwan TWSE/TPEx material-information disclosure rules, board resolutions involving significant capital contributions to subsidiaries must be publicly disclosed. Key details that would normally appear in the full announcement body — including the identity of the subsidiary, the amount of the capital increase, the form of contribution (cash subscription, retained-earnings capitalisation, or asset injection), the funding source, and the strategic rationale — are not available from the subject line alone. [Body not available — subject line only. See MOPS for full announcement.]